Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XVR011 in Hospitalised Mild to Moderate COVID-19
NCT04884295Phase 2Terminated
- Sponsor
- ExeVir Bio
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of VHH72-Fc in coronavirus disease 2019 (COVID-19), sponsored by ExeVir Bio. Started Aug 2021; status: terminated.
02
Drugs
VHH72-Fc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04884295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884295.